Generic Labeling Reg Alternatives Put FDA, Not Firms, In Driver’s Seat
Executive Summary
Some contend the agency is better equipped to make class labeling revisions once a drug has gone generic; in contrast, BIO supports FDA proposed rule but requests clarification on NDA holder’s responsibilities.